News NHS England plans to eliminate hep C by 2025 - with the help... Health chiefs ask pharma to collaborate
News Merck axes hepatitis C drug development Focus shifts to Keytruda amid competition from Gilead and shrinking market.
News Janssen axes hep C development with Achillion Johnson & Johnson has ended a collaboration with US biotech Achillion to develop hepatitis C drugs, sending the US biotech firm's shares plummeting.
News AbbVie, Gilead target sick hepatitis C patients in EU Competing hepatitis C combination drugs from AbbVie and Gilead are now approved in the EU, as the companies aim to treat patients who cannot be cured with established regimens.
News Regulators finally back Merck KGaA oral MS drug A long-awaited oral multiple sclerosis drug from Merck KGaA was among a raft of medicines given the green light by Europe's regulator on Friday.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.